Management of bone health in postmenopausal women

Hormone Research

Volumn 64, Issue SUPPL. 2, 2005, Pages 76-80

  Eastell, Richard ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alendronate; Calcitonin; Osteoporosis; Raloxifene; Risedronate; Teriparatide; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; GESTAGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; FRACTURE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; LEG CRAMP; LONG TERM CARE; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; SMOKING HABIT; STROKE; TASTE; VENOUS THROMBOEMBOLISM; VITAMIN D DEFICIENCY;

ACCIDENTAL FALLS; BONE DENSITY; CALCITONIN; CALCIUM; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK; TERIPARATIDE; THIOPHENES; VITAMIN D;

EID: 27944492455     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087761     Document Type: Conference Paper

References (20)

1. Eastell R: Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-746.
2. Compston J: Prevention and treatment of osteoporosis. Clinical guidelines and new evidence. J R Coll Physicians London 2000;34:518-521.
3. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-995.
4. Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2026.
5. Riggs BL, Parfitt AM: Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-184.
6. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056.
7. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ: Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Br Med J 1994;308:1081-1082.
8. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators: Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-151.
9. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Sääf M, Samsioe G, Verbruggen L, Meunier PJ: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661.
10. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM: Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259-1269.
11. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
12. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.
13. Chesnut C III, Silverman S, Andriano K, Genant HK, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller PD, Moniz C, Peacock M, Richardson P, Watts NB, Baylink DJ, PROOF Study Group: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;109:267-276.
14. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
15. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215.
16. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468.
17. Reginster JY, Seeman E, de Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Díaz CM, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ: Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab, in press.
18. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11(suppl 6):S2-S17.
19. Clowes JA, Peel NF, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-1123.
20. Torgerson DJ, Dolan P: Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998;57:378-379.